Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Tan Sheet

Executive Summary

NAD refers Generix Labs’ BiphedAdrene ads to FTC; ABCO Labs cited for misbranded and unapproved new drugs; FDA warns RockStar on beverage additives; more Regulatory News In Brief.

You may also be interested in...



Trade Groups Expand Caffeine Labeling To Stave Off Tighter Regs

The Council for Responsible Nutrition and the American Herbal Products Association amend guidelines and requirements for labeling and marketing caffeine-containing products, going beyond the law in response to congressional and public health complaints about the ingredient’s safety.

Trade Groups Expand Caffeine Labeling To Stave Off Tighter Regs

The Council for Responsible Nutrition and the American Herbal Products Association amend guidelines and requirements for labeling and marketing caffeine-containing products, going beyond the law in response to congressional and public health complaints about the ingredient’s safety.

Energy Drinks Swayed By Liquid Supplement Draft Guidance After All

Monster Energy products will transition from supplement to conventional food labeling, in a sign that industry may be adapting to FDA’s draft guidance on liquid supplements that stirred controversy upon its publication in 2009.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel